New Delhi: The Drugs Controller General of India (DGCI) on Tuesday gave restricted use to Bharat Biotech’s Covaxin for children between six and 12 years of age.
The company has been asked to submit regular data for the next five months on any adverse effects the vaccine may have. Covaxin is already being given to children above 12 years of age.
The drug authority also granted emergency use of the Corbevax vaccine for children between 5 and 12 years.
Corbevax, manufactured by the Hyderabad-based Biological-E, is India’s first indigenously developed Receptor Binding Domain (RBD) protein sub-unit vaccine.
Further on Tuesday, the drug controller allowed the emergency use of Zycov-D (Zydus Cadila vaccine) for children above 12 years of age.
ZyCoV-D is India’s second indigenously developed coronavirus vaccine after Hyderabad-based Bharat Biotech’s Covaxin.